Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. The company traces its history back to June 2007, when Dr. Liang, its Chairman and Chief Scientific Officer, established Sichuan Clover to develop a new generation of biologics based on the Trimer-Tag technology platform he invented. This proprietary platform enables the development of innovative vaccines and biologics, and forms the scientific foundation of Clover's pipeline. Clover has integrated research and development, manufacturing, and commercial capabilities, and has built strong partnerships with organizations globally. Its diverse pipeline of vaccine candidates aims to meaningfully reduce the burden of vaccine-preventable diseases. The company's areas of focus include vaccines and other diseases, with a notable emphasis on respiratory vaccines such as RSV, hMPV, and PIV3 combination candidates, as well as COVID-19 and seasonal influenza vaccines. In recent years, Clover has advanced several clinical programs. It launched a quadrivalent seasonal influenza vaccine in Mainland China in September 2023 and completed a BLA submission for its seasonal influenza vaccine in Brazil in November 2023. The company has also reported positive clinical data for its RSV vaccine candidate SCB-1019, including head-to-head comparison versus GSK's AREXVY, and has initiated Phase 2 trials for RSV + hMPV ± PIV3 respiratory combination vaccine candidates in older adults. Clover has also expanded access to its COVID-19 vaccine and continues to develop next-generation options. Clover is publicly listed on the Hong Kong Stock Exchange under the ticker 2197.HK. The company operates globally, with a footprint that includes China, the United States, and Brazil, and it remains dedicated to scientific innovation and equitable access to vaccines. Its mission is to harness transformative science and global partnerships to bring innovative vaccines to populations worldwide.

Clover Biopharmaceuticals traces its origins to June 2007, when Dr. Liang, who serves as Chairman and Chief Scientific Officer, established Sichuan Clover. The company was founded with the goal of developing a new generation of biologics based on the Trimer-Tag technology platform, a proprietary system invented by Dr. Liang. This platform became the scientific cornerstone of Clover's research and development efforts. Over the years, Clover evolved into a global commercial-stage biotechnology company with integrated research and development, manufacturing, and commercial capabilities. It built partnerships with organizations worldwide and assembled a diverse pipeline of vaccine candidates aimed at reducing the burden of vaccine-preventable diseases. The company's mission is to harness transformative science and global partnerships to bring innovative vaccines to populations worldwide. A significant chapter in Clover's history was its response to the COVID-19 pandemic. The company developed a COVID-19 vaccine and worked to expand access to it while continuing to develop next-generation options. This effort raised Clover's global profile and demonstrated its ability to advance candidates from development toward commercialization. In the years that followed, Clover broadened its vaccine portfolio. In September 2023, it launched a quadrivalent seasonal influenza vaccine in Mainland China, marking a major commercial milestone. In November 2023, the company completed a BLA submission for its seasonal influenza vaccine in Brazil, signaling its intent to serve international markets. Around the same time, Clover initiated a Phase I clinical trial for its RSV vaccine candidate and reported positive Phase I results for SCB-219M, a treatment for chemotherapy-induced thrombocytopenia (CIT). Clover's RSV program advanced rapidly. In April and June 2024, the company announced positive preliminary Phase I results for its bivalent RSV vaccine candidate SCB-1019 in young adult and older adult cohorts, respectively. In October 2024, Clover reported positive clinical data for SCB-1019 compared head-to-head versus GSK's AREXVY, a notable achievement in the competitive RSV vaccine field. In March 2025, Clover announced U.S. IND clearance and the initiation of a revaccination clinical study for SCB-1019. The company then initiated Phase I and Phase II trials for RSV + hMPV ± PIV3 respiratory combination vaccine candidates in 2025 and 2026, and reported positive Phase I and Phase 2 data in older adults. In October 2025, Clover appointed Nicholas Jackson, Ph.D., as President of Global R&D and Alliances, strengthening its leadership team. Today, Clover Biopharmaceuticals is publicly listed on the Hong Kong Stock Exchange (ticker 2197.HK) and operates globally, with activities spanning China, the United States, Brazil, and other markets. The company remains focused on scientific innovation and equitable access to vaccines, with a pipeline that includes respiratory combination vaccines, RSV, influenza, and COVID-19 candidates.

• Dr. Liang establishes Sichuan Clover to develop a new generation of biologics based on the Trimer-Tag technology platform.

• Clover launches quadrivalent seasonal influenza vaccine in Mainland China.

• Clover completes BLA submission for seasonal influenza vaccine in Brazil.

• Clover initiates Phase I clinical trial for RSV vaccine candidate.

• Clover announces positive Phase I results for SCB-219M for treatment of chemotherapy-induced thrombocytopenia (CIT).

• Clover announces positive preliminary Phase I results for bivalent RSV vaccine candidate SCB-1019 in initial young adult cohort.

• Clover announces positive preliminary Phase I results for bivalent RSV vaccine candidate SCB-1019 in older adults.

• Clover announces positive clinical data for RSV vaccine candidate SCB-1019 compared head-to-head versus GSK’s AREXVY.

• Clover announces U.S. IND clearance and initiation of revaccination clinical study for RSV vaccine candidate SCB-1019.

• Clover initiates Phase I clinical trial for RSV + hMPV ± PIV3 respiratory combination vaccine candidates.

• Clover announces positive Phase I clinical data for RSV-hMPV-PIV3 combination vaccines and for RSV re-vaccination in older adults.

• Clover appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances.

• Clover initiates Phase 2 clinical trial for RSV + hMPV ± PIV3 respiratory combination vaccine candidates.

• Clover announces additional positive U.S. Phase I clinical data for RSV re-vaccination in older adults.

• Clover announces positive Phase 2 clinical data for RSV + hMPV ± PIV3 respiratory combination vaccine candidates in older adults.

Global commercial-stage biotechnology company focused on innovative vaccines using its proprietary Trimer-Tag technology platform.

• Quadrivalent seasonal influenza vaccine

  Launched in Mainland China in September 2023; BLA submitted in Brazil in November 2023.

• COVID-19 vaccine

  Clover is expanding access to its COVID-19 vaccine and developing next-generation options.

• SCB-1019 (RSV vaccine candidate)

  Bivalent RSV vaccine candidate; positive Phase I results in young adults and older adults; head-to-head comparison versus GSK's AREXVY; U.S. IND clearance for revaccination study.

• RSV + hMPV ± PIV3 respiratory combination vaccine candidates

  Combination vaccine candidates in Phase 1 and Phase 2 clinical trials for older adults.

• SCB-219M

  Treatment for chemotherapy-induced thrombocytopenia (CIT); positive Phase I results announced in December 2023.

• Unconfirmed

  Clover Biopharmaceuticals files for Hong Kong IPO[6]科兴生物制药申请在香港上市caixinglobal.com

  Clover Biopharmaceuticals filed for an initial public offering in Hong Kong. The company did not disclose the offering size; Goldman Sachs and CICC will sponsor the listing.

• 2020-07-08

  CEPI and Clover expand vaccine-development partnership[7]CEPI与Clover扩大疫苗研发合作finanznachrichten.de

  Reported: 2020-07-08

  CEPI announced an expanded partnership with Clover to advance development and manufacture of Clover’s S-Trimer COVID-19 vaccine candidate. CEPI will make an additional $66 million upfront investment to support clinical development and manufacturing scale-up.

• 2020-04-27

  CEPI and Clover Australia announce COVID-19 vaccine development partnership[8]CEPI与Clover Australia宣布新冠疫苗研发合作ibtimes.com.au

  Reported: 2020-04-27

  CEPI announced a partnership with Clover Biopharmaceuticals AUS Pty Ltd (Clover Australia), including an initial US$3.5 million investment to support preparation and initiation of an Australian phase 1 trial of Clover’s COVID-19 S-Trimer vaccine candidate.

1. 1Clover Biopharmaceuticals | Homecloverbiopharma.com
2. 2Clover Biopharmaceuticals | Our Companycloverbiopharma.com
3. 3Clover Biopharmaceuticals | Company Newscloverbiopharma.com
4. 4Clover Biopharmaceuticals | Our Culturecloverbiopharma.com
5. 5Clover Biopharmaceuticals Inc. - Wikidatawikidata.org
6. 6科兴生物制药申请在香港上市caixinglobal.com
7. 7CEPI与Clover扩大疫苗研发合作finanznachrichten.de
8. 8CEPI与Clover Australia宣布新冠疫苗研发合作ibtimes.com.au